VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2016

Feb 4, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2016-02-02

Reporting Person: Sachdev Amit (EVP, Policy, Access & Value)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-02	Common Stock	A	17299	$0.01	Acquired	96262	Direct
2016-02-03	Common Stock	S	4300	$89.91	Disposed	91962	Direct
2016-02-03	Common Stock	S	3700	$91.01	Disposed	88262	Direct
2016-02-03	Common Stock	S	900	$91.82	Disposed	87362	Direct
2016-02-03	Common Stock	S	1266	$92.79	Disposed	86096	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-02	Stock Option (Right to Buy)	$91.05	A	34482	Acquired	2026-02-01	Common Stock (34482)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	882	Indirect

Footnotes

F1: Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019.

F2: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.

F3: Open market sales reported on this line occurred at a weighted average price of $89.91 (range $89.31 to $90.27).

F4: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5: Open market sales reported on this line occurred at a weighted average price of $91.01 (range $90.37 to $91.35).

F6: Open market sales reported on this line occurred at a weighted average price of $91.82 (range $91.37 to $92.26).

F7: Open market sales reported on this line occurred at a weighted average price of $92.79 (range $92.42 to $93.11).

F8: The option vests in 16 quarterly installments from 02/02/2016.